Table 4.
Comparison of ICH Risk With Recent Retrospective Studies
| Author/year | Population | Population Categories | ICH | P Value | ||||
|---|---|---|---|---|---|---|---|---|
| VTE on AC | VTE Not on AC | Non-VTE | VTE on AC | VTE Not on AC | Non-VTE | |||
| Khoury et al/2016 | GBM n = 173 |
97 (56%) | 76 (44%) | – | Incidence = 15 (15.5%) | Incidence = 2 (2.6%) | – | .005 |
| Mantia et al/2017 | HGG n = 133 |
50 (38%) | – | 83 (62%) | 1-yr CI = 28.1% | – | 1-yr CI = 13.6% | .37 |
| Al Megren et al/2017 | Glioma n = 152 |
70 (46%) | 6 (4%) | 76 (50%) | Incidence = 11 (15.7%) | Incidence = 2 (2.4%) | .011 | |
| Carney et al/2019 | Glioma n = 67 |
47 (70%)a | – | – | 1-yr CI = 36.8% | – | – | – |
| Current study | HGG n = 220 |
88 (40%) | 22 (10%) | 110 (50%) | 1-yr CI = 17% | 1-yr CI = 9% | 1-yr CI = 13% | .36b |
Abbreviations: 1-yr CI, cumulative incidence at 1 year; AC, anticoagulation; HGG, high-grade glioma; ICH, intracranial hemorrhage; VTE, venous thromboembolism.
aPatients treated with enoxaparin only; patients treated with direct oral anticoagulant in this study were not reported in this table.
bGray’s test between VTE on AC group vs VTE not on AC group.